VNDA
Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.09
+1.49%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.06
From 52W high−57.22%
Volume670403.00
Market cap$247.29M
P/E (TTM)—
P/S (TTM)1.1x
Div yield—
Key dataOct 19, 2026
Open
$4.06
From 52W high
−57.22%
Volume
670403.00
Market cap
$247.29M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
27.0
MomentumView details →
1D Return
+1.49%
YTD Return
−53.40%
SummaryUpdated Jun 1, 2026
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a biopharmaceutical company founded in 2002 and headquartered in Washington, D.C. The company went public in April 2006 and focuses on developing and commercializing therapies to address high unmet medical needs, particularly in the areas of sleep disorders, psychiatric conditions, and other central nervous system disorders. Vanda has successfully brought several products to market and maintains a robust pipeline of investigational therapies across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Vanda Pharmaceuticals Inc. put its anxiety-drug program on hold.5d agoVanda Pharmaceuticals reported that its Phase III Study 3201 of VQW-765 for on-demand treatment of acute anxiety in adults with social anxiety disorder did not meet its primary endpoint.6d agoVanda Pharmaceuticals announced positive topline Phase III results for HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder, meeting its primary endpoint.20d ago